Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
ondansetron hydrochloride
Medication labelWhy this: Advisory · dailymed-prescription
Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin. Efficacy of the 32 mg single dose beyond 24 hours in these patients has not been established. Prevention of postoperative nausea and/or vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided postoperatively, ondansetron injection, USP is recommended even where the incidence of postoperative nausea and/or vomiting is low. For patients who do not receive prophylactic ondansetron injection, USP and experience nausea and/or vomiting postoperatively, ondansetron injection, USP may be given to prevent further episodes (see CLINICAL TRIALS).
- generic_name
- ondansetron hydrochloride
- product_names
- Ondansetron Hydrochloride
- ndc
- 54868-5888, 62778-027, 54868-5888-0
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en